The presence of NRAS mutations among patients with de novo AML, secondary AML, and therapy-related AML were similar, present in 10% of patients with de novo AML, 12.1% in patients with secondary AML, and 10.9% of patients with therapy-related AML [187]. The gene discussed is NRAS; the disease is acute myeloid leukemia.